-
RBC Capital on Pacira Pharmaceuticals (PCRX): 'regulatory approval of the generic form is just one piece of a larger puzzle'
-
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
-
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
-
RBC Capital Remains Bullish on Pacira Pharmaceuticals (PCRX) Following Earnings: 'We expect improving sales trends to continue'
-
Pacira BioSciences to Present at Two Healthcare Conferences in May
-
Pacira BioSciences to Present at Two Healthcare Conferences in May
-
Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference
-
Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference
-
Pacira Pharmaceuticals (PCRX) PT Raised to $78 at RBC Capital
-
Pre-Open Stock Movers 07/07: (NVAX) (VSLR) (RUN) Higher; (EOLS) (CLLS) (MARK) Lower (more...)
-
Pacira Pharma (PCRX): HRTX CRL a 'Clear Positive' - RBC
-
Pacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
-
Pacira BioSciences to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
-
Pacira Pharmaceuticals (PCRX) is Set to Break Out in 2020 - RBC Capital
-
Pacira BioSciences to Present at Two Healthcare Conferences in May
-
Pacira BioSciences to Present at Two Healthcare Conferences in May
-
Pacira Pharmaceuticals (PCRX) PT Raised to $65 at RBC Capital
-
Pacira Pharmaceuticals (PCRX) PT Raised to $60 at RBC Capital
-
Pacira Pharmaceuticals (PCRX) PT Raised to $55 at RBC Capital
-
Pacira Pharmaceuticals (PCRX) PT Raised to $50 at RBC Capital
-
Pacira Pharma (PCRX): CMS Decision for EXPAREL Still Awaited - RBC
-
Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference
-
Pacira Pharmaceuticals to Present at the 2018 RBC Capital Markets Healthcare Conference
-
Pacira Pharmaceuticals (PCRX) PT Lowered to $50 at RBC Capital Ahead of 3Q Release
-
Pacira Pharma (PCRX) to Invest $25M in TELA Bio
-
Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement
-
Pacira Pharma (PCRX): Early Survey Results Are Encouraging On JNJ Selling Efforts - RBC
-
Pacira Pharma (PCRX): Expecting A 10-15% Move Imminently - RBC
-
RBC Capital Starts Pacira Pharmaceuticals (PCRX) at Outperform
-
Pacira Pharmaceuticals, Inc. to Present at the 2017 RBC Capital Markets’ Healthcare Conference

